NANOSOMIX

Company Overview

NanoSomiX Inc. is working to develop non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using brain-derived exosomes (BDE). NanoSomiX has developed a suite of assays that can measure biomarkers from BDE using a simple blood draw.

NanoSomiX is currently involved in several collaborative research projects with new markers and clinical applications in multiple settings. The company uses the service lab approach as its business model. It is involved in translating innovative research advancements using exosomes in the blood into clinically applicable LTDs. It is open to working with researchers and investigators under contract or research collaborations utilizing its proprietary technology to further the role of BDE in neurologic basic and clinical research. The clinical areas currently targeted include postoperative delirium and cognitive decline, traumatic brain injuries (TBI), including sports concussion, and stroke.

Company's Business Segments

• Non-invasive Testing : The company provides noninvasive testing to address the requirements for improved brain analytic tools that utilize Brain-Derived Exosomes (BDE) for research and clinical applications.